01.13.2025
Drug Discovery as it will be
Pioneering AI and Robotics in Drug Discovery
Iktos leverages cutting-edge AI and robotics to transform drug discovery. By integrating the creativity of Generative AI with automated synthesis and testing, we are forging a path towards fully autonomous labs, accelerating the development of new treatments to improve patient care.
Follow a molecule’s journey through Iktos’s platform, from inception to drug candidate, iterating through the DMTA cycle.
Embark on the Molecular
Odyssey
The journey begins with Makya's AI-driven design, continues with Spaya's efficient retrosynthesis, and advances through Iktos Robotics for synthesis, purification, analysis, and testing. This integrated approach shortens the discovery phase to under 2 years.
Innovative molecular Design
Generative AI
Makya
Makya, our generative AI SaaS platform, starts the molecular journey by creating diverse, novel, and medchem-like molecules. With its unique chemistry driven approach, it ensures each molecule is synthetically accessible and optimized for success.
Key Features
- Generative AI technology for de novo drug design
- Focus on synthetic accessibility
- Multi-parametric optimization
- Inclusion of 3D constraints
Efficient Synthesis Planning
Retrosynthesis AI
Spaya
The next step in the journey involves Spaya, our AI-driven retrosynthesis platform. Spaya quickly identifies the most feasible synthetic routes, converting target compounds into commercially available starting materials. This data-driven approach ensures the synthesis process is optimized, tailored to your needs, and compatible with our robotic systems.
Key Features
- Real-time display of retrosynthetic routes
- Customizable synthesis steps and constraints
- Integration with various data providers
Comprehensive Automation
Autonomous Lab
Iktos Robotics Chemistry
Iktos' generative AI, Makya, designs molecules optimized for robotic synthesis. Our AI-driven autonomous Lab manages the complete synthetic process, from workflow management and ordering raw materials to executing chemical synthesis. This evolving AI-driven DMTA (Design-Make-Test-Analysis) process significantly reduces the time to identify viable drug candidates.
Key Features
- Fully automated synthesis and analysis
- High-throughput data generation and iteration
- Ongoing Integration: Purification
Multidimensional biological data
In-cellulo screening
Iktos Robotics Biology
Iktos' generative AI, Makya, is guided with multidimensional biological data generated from our high-throughput imaging platform. It identifies small-molecule modulators of protein activity, protein-protein and RNA-protein interactions, captured in biologically relevant environments. This enables the continuous optimization of molecular properties, ensuring that each cycle brings us closer to the ideal drug candidate - even for the most challenging targets.
Key use cases
- Protein-Protein interactions
- RNA-Protein interactions
- Protein-Protein Self-Assembly
- Molecular glues and PROTACs
Our in-house Pipeline
Our in-house pipeline showcases our capability to apply our AI and robotics technology across various stages of drug development, from target identification to preclinical candidate.
Partner with Iktos
Embark with us
Since our inception in 2016, we have consistently delivered value through over 60+ collaborations with leading pharmaceutical, biotech, and academic institutions. Our highly skilled team is dedicated to pushing the boundaries of AI-driven drug design, making us a trusted partner in your molecular odyssey.
Explore our Resources
